Bionoxx to Present New Strategy for Immune Diseases at 2024 BIO Conference

Bionoxx Inc., a pioneering biotech firm, is set to debut its cutting-edge immunomodulatory technology at the 2024 BIO International Convention. The presentation is scheduled for Tuesday, June 4, 2024, at 4:00 PM PT, in San Diego and Seoul, South Korea, as announced on May 23, 2024.

Bionoxx has discovered that cancer patients often experience disrupted neutrophil homeostasis in their peripheral blood, a condition believed to contribute to T cell dysfunction and subsequently poorer clinical outcomes. To address this, Bionoxx has developed BNX-IFS, an innovative technology that identifies activated neutrophils crucial for T cell homeostasis within circulating immune cells. The United States Food and Drug Administration (FDA) has recently approved Bionoxx’s Investigational New Drug (IND) application to commence the first human clinical trial of mOTS-412, either alone or in combination with anti-PD-L1, in patients with tumors resistant to immune checkpoint inhibitors. This trial is slated to begin in the latter half of 2024 in the United States.

Dr. Tae-Ho Hwang, Bionoxx's Chief Technology Officer, remarked that the FDA's acceptance of their IND application is a pivotal step in advancing their immunomodulatory pipeline. This approval not only validates the BNX-IFS technology but also offers a new platform to develop treatment regimens for immune-related conditions.

BNX-IFS, or Bionoxx's Immune Function States, is a groundbreaking technology that analyzes disease-associated immune dynamics within circulating immune cells. This technology has unveiled the role of neutrophil plasticity in managing T cell homeostasis, a finding supported by nonclinical disease models and clinical specimens from both healthy individuals and patients with immune-related ailments. Bionoxx aims to use BNX-IFS as a personalized tool to optimize T cell balance in various immune-mediated diseases.

In addition to BNX-IFS, Bionoxx is developing OTS-412, an investigational oncolytic virus designed to complement the company's immunomodulatory strategies by targeting and destroying cancer cells. This approach enhances cancer-specific cytotoxic T cell immunity and, in nonclinical models, has shown a synergistic anti-tumor effect when used with immune checkpoint inhibitors (ICI).

Bionoxx Inc., headquartered in South Korea, focuses on leveraging neutrophil-directed T cell modulation to combat cancer and immune disorders. The company is committed to improving clinical outcomes for patients by customizing immunotherapies using their innovative technologies. Bionoxx is also actively seeking collaborations and partnerships for the discovery and development of treatments for cancer and immune-mediated diseases, including acute viral infections and autoimmune disorders.